KRYS - Total Utang marang Modal Krystal Biotech Corp.

Logo perusahaan publik Krystal Biotech, Inc. (KRYS)

This chart of the current share price of Krystal Biotech, Inc. (KRYS) demonstrates a debt-to-equity ratio of 0.01. Krystal Biotech, Inc. (KRYS) possesses exceptional pricing power due to its unique local gene delivery method. Effective collaboration with external contractors ensures stable product output. However, business success relies on test results, insurance company recognition, and the patent purity of its developments.

KRYS: Total Utang marang Modal Krystal Biotech 04.07.2022 - 31.10.2026

Rincian analitis perusahaan Krystal Biotech, Inc.

- rega lan prakiraan konsensus rega:
Bagan rega Krystal Biotech|KRYS - Bagan tingkat prakiraan
- statistik kapitalisasi pasar:
Kapitalisasi pasar Krystal Biotech|KRYS - Nilai Dipunlarasaken Utang lan Kas
- indikator kapitalisasi buku:
Nilai Buku saben Saham Krystal Biotech|KRYS - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku krystalbio.com|KRYS - Nilai Agregat Aset
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas Krystal Biotech, Inc.|KRYS - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Krystal Biotech, Inc.|KRYS - Gunggung utang perusahaan|Utang marang nilai buku Krystal Biotech|KRYS - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Krystal Biotech|Likuiditas cepet krystalbio.com
- informasi bathi lan kelipatan valuasi:
KRYS - Bathi resik
Analisis dhasar perusahaan:Krystal Biotech
Barang utama Krystal Biotech Corp.

The total debt-to-equity ratio measures the extent to which business financing relies on borrowed funds relative to equity, reflecting the company's financial stability. By analyzing this total debt/equity chart, an investor can see the impact of share price on leverage, which is critically important for Krystal Biotech, Inc. (KRYS) given the capital-intensive development of autonomous ultra-low temperature logistics systems for gene therapies.

Analisis pesaing Krystal Biotech, Inc.

Utang marang Ekuitas Apogee Therapeutics, Inc.|Arcutis - Utang Agregat marang Ekuitas|Total Utang marang Modal VCEL|ORKA (Oruka Pharma) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal SMTI (Sanara MedTech)|Total Utang marang Modal DBV Tech DBVT|SLSN - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi DERM (Journey Medical)|Forte Biosciences, Inc (FBRX) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Empro Corporation|SLGL (Sol-Gel Technologies) - Total Utang marang Modal|Total Utang marang Modal Revive Pro Care|Rasio Total Utang marang Ekuitas MDCX (Medicus Pharma)|VRCA (verrica.com) - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Hoth Therapeutics HOTH|Koefisien Total Utang marang Modal Biofrontera, Inc. (BFRI)|VYNE - Utang marang Ekuitas|SNOA - Total Utang marang Modal|QNRX: Total Utang marang Modal|AZTR - Koefisien Total Utang marang Modal|Utang marang Ekuitas Dermata|Rasio Utang marang Ekuitas ELAB (Elevai Corp)|Utang marang Ekuitas Revance Therapeutics (RVNC)